Today's case was of a middle-aged man with renal
cell carcinoma. He was sent in for an acute rise in his serum creatinine following a nephrostomy change.
We talked about
multiple valuable learning points:
-Acute kidney injury
(formerly acute renal failure) is one of the most common inpatient referrals
that we see as internists. Although the
approach is very rudimentary, it is quite helpful to at least entertain three
categories of possible causes in your mind:
-Pre-renal causes: by
definition, pre-renal causes will correct
completely once circulating volume has been restored. On history look for things like reduced PO
intake, diarrhea, blood loss, etc. Also,
certain volume overloaded states like cardiorenal syndrome or hepatorenal
syndrome behave as pre-renal AKI because as far as the kidney is concerned,
there is reduced circulating volume.
-Post-renal causes:
these relate to obstruction and back pressure on the collecting system of the
kidney producing hydronephrosis and reduced urinary flow. Keep in mind that most people have two
functioning kidneys, meaning that severe AKI usually only occurs with lesions
below the bladder (obstructing flow to both kidneys) or large retroperitoneal
masses that directly compress both ureters.
Our patient has one kidney, so something like a stone or blocked
nephrostomy tube would be sufficient to cause AKI.
-Intrinsic renal
causes: The simplest way to divide these up is to think of the structures
within the kidney. Glomerular causes of
AKI include things that cause acute glomerulonephritis (post-infectious,
autoimmune/vasculitis, infectious/viral).
Tubular causes like acute tubular necrosis can occur because of drugs or
insufficient circulating volume for sufficient time to induce
injury/damage. Interstitial causes of
AKI can result from infection, autoimmune processes, or most commonly drugs
(PPI’s are a common medication that can do this). Finally, vascular causes in the
microcirculation can also cause AKI (TTP, HUS, etc.). Also, macrovascular complications like
obstructive tumours or thrombi can lead to AKI through a variet of mechanisms.
-The approach to AKI
is two-fold: firstly, you need to try to determine the cause. Our usual assessment includes a history and
physical examination focusing on volume status and indications for
dialysis. Almost every patient with AKI
should have urine electrolytes (low urine sodium suggest a pre-renal cause), a
urinalysis (blood suggests GN or ATN), a urine microscopy to look for casts,
and an abdominal ultrasound or other imaging to exclude hydronephrosis.
-Once you’ve finished
your assessment portion, you need to look at a few management things. Always start with ABC’s (e.g. if the patient
is in florid pulmonary edema, he probably requires respiratory support). Following that, ensure that the patient is
adequately volume replete – pre-renal AKI can
cause a creatinine of 1000umol/L that corrects with fluid. Then ensure that there are no medications
causing the AKI (antibiotics, NSAIDS, chemotherapy, etc). After that, ensure that there are no medications
that can worsen the AKI (ACE
inhibitors, ARBs, diuretics). Finally, ensure
that any medications that need to be adjusted or held in renal failure are
examined (digoxin, antibiotics, etc.).
-We talked about
indications for dialysis. Briefly, they
can be divided into the mnemonic AEIOU.
A = refractory
acidosis
E = refractory
electrolyte abnormalities (principally potassium or calcium)
I = intoxication
(methanol, ethylene glycol, ASA, lithium)
O = refractory volume
overload/heart failure
U = uremic
pericarditis or uremic encephalopathy (asterixis)
For the most part,
there is no survival advantage to early dialysis before one of these
indications is met. Furthermore, it is
generally not advisable to use dialysis (or bicarbonate infusion for that
matter) to treat lactic acidosis from hypoperfusion. The best treatment is correcting the
underlying cause (usually shock) because some of the physiologic changes
associated with acidosis are actually adaptive.
-Finally, we talked a
little bit about Septra®/Cotrimoxazole/Trimethoprim-Sulfamethoxazole. There are a couple of things to recognize
about this medication. The spectrum that
it has is actually quite broad, and it is on the common list of first-line
agents for urinary tract infections.
This drug is highly bioavailable
when taken orally, so there is almost never an indication to use the
intravenous formulation. The gram
positive coverage is generally very good, and this drug can be used to treat
infections with methicillin-resistant
Staphylococcus Aureus (MRSA).
-That said, it is
quite old and has a number of side effects.
Septra has been associated with Stevens-Johnson Syndrome/Toxic Epidermal
Necrolysis, it has many drug
interactions because of its inhibition of cytochrome P450 hepatic enzymes, it
can cause bone marrow suppression and cytopenias, and can cause AKI. Additionally, the trimethoprim component
actually behaves like a potassium-sparing diuretic leading to hyperkalemia
independent of renal failure.
Furthermore, the sulfamethoxazole component behaves like a sulfonylurea
secretagogue which can lead to hypoglycemia. There have been associations between Septra
and sudden death, presumably on the basis of hyperkalemia, in database studies.
Further Reading:
Fralick, M.,
Macdonald, E. M., Gomes, T., Antoniou, T., Hollands, S., Mamdani, M. M., &
Juurlink, D. N. (2014). Co-trimoxazole and sudden death in patients receiving
inhibitors of renin-angiotensin system: population based study. BMJ, 349,
g6196.
Star, R. A. (1998).
Treatment of acute renal failure. Kidney international, 54(6),
1817-1831.